文献速递肝肾功能剂量调整

格列帕鲁肽在肾功能不全受试者中的药代动力学、安全性与耐受性

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment.
PubMed 文献 · Clin Pharmacokinet · 2023-02-21

本研究为3中心、非随机、开放标签研究,纳入16名受试者,比较严重肾功能不全、终末期肾病(ESRD)未透析患者与肾功能正常对照者单次皮下注射格列帕鲁肽10 mg后的药代动力学。结果显示,严重肾功能不全/ESRD患者与肾功能正常者之间总暴露量(AUC0-168 h)和峰浓度(Cmax)无临床相关差异;单次给药安全且耐受良好,未报告严重不良事件。结论认为肾功能不全的短肠综合征患者无需调整剂量。

要点

  • 严重肾功能不全或ESRD未透析患者与肾功能正常者相比,格列帕鲁肽总暴露和峰浓度无临床相关差异。
  • 单次皮下注射格列帕鲁肽10 mg在肾功能正常及严重肾功能不全/ESRD受试者中安全且耐受良好。
  • 基于该试验,短肠综合征合并肾功能不全患者无需调整格列帕鲁肽剂量。

核心结论

  • 格列帕鲁肽在严重肾功能不全/ESRD受试者与肾功能正常受试者之间的药代动力学无差异,肾功能不全的短肠综合征患者无需调整剂量。

研究设计与样本

  • 3中心、非随机、开放标签研究,共纳入16名受试者:4例严重肾功能不全(eGFR 15至<30 mL/min/1.73 m2)、4例终末期肾病未透析(eGFR<15 mL/min/1.73 m2)、8例肾功能正常对照(eGFR≥90 mL/min/1.73 m2)。
  • 受试者单次皮下注射格列帕鲁肽10 mg,采血持续14天,主要药代动力学参数为AUC0-168 h和Cmax。

主要发现

  • 严重肾功能不全/ESRD受试者与肾功能正常受试者相比,单次皮下注射格列帕鲁肽后的总暴露量(AUC0-168 h)和峰浓度(Cmax)无临床相关差异。
  • 单次皮下注射格列帕鲁肽10 mg在肾功能正常及严重肾功能不全/ESRD受试者中安全且耐受良好,未报告严重不良事件,未发现安全性问题。

临床怎么用

  • 对于短肠综合征合并肾功能不全(包括严重肾功能不全或ESRD未透析)的患者,使用格列帕鲁肽时无需根据肾功能调整剂量。

局限性

  • 本研究为非随机、开放标签设计,样本量较小(共16例),可能影响结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glepaglutide is a novel, ready-to-use, long-acting, glucagon-like peptide-2 (GLP-2) analog intended for the treatment of patients with short bowel syndrome (SBS). This study investigated the impact of renal function on the pharmacokinetics and safety of glepaglutide. METHODS: In this 3-site, non-randomized, open-label study, 16 subjects were enrolled: 4 with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), 4 with end stage renal disease (ESRD) not on dialysis (eGFR < 15 mL/min/1.73 m2), and 8 matching controls with normal renal function (eGFR ≥ 90 mL/min/1.73 m2). Blood samples were collected over a 14-day period following a single subcutaneous (SC) dose of glepaglutide 10 mg. Safety and tolerability were assessed throughout the study. The primary pharmacokinetic parameters were area under the curve between dosing and 168 h (AUC0-168 h) and the maximum plasma concentration (Cmax). RESULTS: There was no clinically relevant difference between subjects with severe renal impairment/ESRD and normal renal function with respect to total exposure (AUC0-168 h) and peak plasma concentrations (Cmax) of glepaglutide following a single SC dose. A single SC dose of glepaglutide 10 mg appeared safe and well tolerated in subjects with normal renal function and subjects with severe renal impairment or ESRD. No serious adverse events were reported, and no safety issues were identified. CONCLUSIONS: No difference in glepaglutide pharmacokinetics was seen between renal impaired and normal subjects. Based on this trial, dose adjustment appears not to be warranted in SBS patients with renal impairment. TRIAL REGISTRATION: The trial is registered at http://www. CLINICALTRIALS: gov (NCT04178447) and has the EudraCT number: 2019-001466-15.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Agersnap MA, Sonne K, Knudsen KM, et al. Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment. Clin Pharmacokinet. 2023. PMID: 36811175. doi:10.1007/s40262-023-01215-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。